Advances of cancer-associated fibroblasts in liver cancer.
CCA
HCC
Liver cancer
cancer-associated fibroblasts
Journal
Biomarker research
ISSN: 2050-7771
Titre abrégé: Biomark Res
Pays: England
ID NLM: 101607860
Informations de publication
Date de publication:
16 Aug 2022
16 Aug 2022
Historique:
received:
26
05
2022
accepted:
01
08
2022
entrez:
15
8
2022
pubmed:
16
8
2022
medline:
16
8
2022
Statut:
epublish
Résumé
Liver cancer is one of the most common malignant tumors worldwide, it is ranked sixth in incidence and fourth in mortality. According to the distinct origin of malignant tumor cells, liver cancer is mainly divided into hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Since most cases are diagnosed at an advanced stage, the prognosis of liver cancer is poor. Tumor growth depends on the dynamic interaction of various cellular components in the tumor microenvironment (TME). As the most abundant components of tumor stroma, cancer-associated fibroblasts (CAFs) have been involved in the progression of liver cancer. The interplay between CAFs and tumor cells, immune cells, or vascular endothelial cells in the TME through direct cell-to-cell contact or indirect paracrine interaction, affects the initiation and development of tumors. Additionally, CAFs are not a homogeneous cell population in liver cancer. Recently, single-cell sequencing technology has been used to help better understand the diversity of CAFs in liver cancer. In this review, we mainly update the knowledge of CAFs both in HCC and CCA, including their cell origins, chemoresistance, tumor stemness induction, tumor immune microenvironment formation, and the role of tumor cells on CAFs. Understanding the context-dependent role of different CAFs subsets provides new strategies for precise liver cancer treatment.
Identifiants
pubmed: 35971182
doi: 10.1186/s40364-022-00406-z
pii: 10.1186/s40364-022-00406-z
pmc: PMC9380339
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
59Subventions
Organisme : National Natural Science Foundation of China
ID : 81872255
Organisme : Leading-edge Technology Programme of Jiangsu Natural Science Foundation
ID : BK20212021
Informations de copyright
© 2022. The Author(s).
Références
Gastroenterology. 2014 Jul;147(1):41-7
pubmed: 24814904
Cancer Manag Res. 2019 Jun 24;11:5737-5744
pubmed: 31296998
JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Mol Cancer. 2018 Dec 28;17(1):178
pubmed: 30593276
Neoplasia. 2019 Dec;21(12):1133-1142
pubmed: 31759251
Mol Cell. 2017 Oct 19;68(2):281-292.e5
pubmed: 29033320
J Biol Chem. 2001 Mar 9;276(10):7408-14
pubmed: 11084048
Mod Pathol. 2021 Feb;34(2):408-416
pubmed: 32860001
Int J Biol Sci. 2022 Jan 1;18(1):43-64
pubmed: 34975317
Hepatology. 2016 Jul;64(1):117-29
pubmed: 26910875
Nat Commun. 2013;4:2823
pubmed: 24264436
Acta Biochim Biophys Sin (Shanghai). 2020 Jan 2;52(1):18-25
pubmed: 31828297
Cancer Res. 2018 Feb 15;78(4):938-949
pubmed: 29259010
Cell Rep. 2022 Feb 8;38(6):110349
pubmed: 35139382
Breast Cancer Res Treat. 2019 Jan;173(1):55-64
pubmed: 30302588
Mod Pathol. 2003 Oct;16(10):1019-27
pubmed: 14559985
Hepatology. 2010 Mar;51(3):1027-36
pubmed: 20052656
Oncotarget. 2015 May 20;6(14):12061-79
pubmed: 25909286
Hepatology. 2013 Sep;58(3):1042-53
pubmed: 23505219
Hepatology. 1996 Jun;23(6):1341-4
pubmed: 8675149
Int J Cancer. 2010 Dec 1;127(11):2576-87
pubmed: 20162672
Cancer Res. 2018 Apr 1;78(7):1619-1631
pubmed: 29363547
Oncogenesis. 2016 Feb 22;5:e198
pubmed: 26900950
Int J Oncol. 2021 Aug;59(2):
pubmed: 34195849
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Int J Cancer. 2008 Nov 15;123(10):2229-38
pubmed: 18777559
Liver Int. 2019 May;39 Suppl 1:63-78
pubmed: 30907492
Hepatology. 2010 Feb;51(2):523-34
pubmed: 19821534
J Hepatol. 2020 Nov;73(5):1118-1130
pubmed: 32505533
Oncogenesis. 2019 May 16;8(6):36
pubmed: 31097694
Acta Biomater. 2018 Aug;76:146-153
pubmed: 30078422
J Pathol. 2021 Oct;255(2):212-223
pubmed: 34228359
Cancer Res. 2016 Jul 15;76(14):4124-35
pubmed: 27216177
Oncol Rep. 2013 Sep;30(3):1143-8
pubmed: 23807641
Cancer Sci. 2021 Sep;112(9):3545-3554
pubmed: 34159680
Hepatology. 2019 Oct;70(4):1409-1423
pubmed: 31004519
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):223-238
pubmed: 33349658
J Hepatol. 2021 Apr;74(4):860-872
pubmed: 33221352
Nat Cell Biol. 2020 Jun;22(6):728-739
pubmed: 32367049
FEBS J. 2016 Jun;283(12):2219-32
pubmed: 26807763
Cancer Res. 2001 Mar 15;61(6):2696-703
pubmed: 11289150
Curr Drug Targets. 2018;19(13):1573-1588
pubmed: 29468965
Sarcoma. 2016;2016:5213628
pubmed: 27057137
Nat Rev Mol Cell Biol. 2016 Oct;17(10):611-25
pubmed: 27461391
PLoS One. 2013 Oct 08;8(10):e76830
pubmed: 24116172
Cancer Lett. 2007 Jun 8;250(2):237-49
pubmed: 17137709
Oncogene. 2022 Mar;41(10):1410-1420
pubmed: 35031773
Cell Rep. 2016 May 10;15(6):1175-89
pubmed: 27134167
J Cancer Res Clin Oncol. 2020 Dec;146(12):3255-3268
pubmed: 32870388
Mol Carcinog. 2018 Dec;57(12):1735-1750
pubmed: 30136419
Hum Pathol. 2017 Jul;65:92-100
pubmed: 28457731
Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):999-1003
pubmed: 8430113
Cells. 2019 Apr 03;8(4):
pubmed: 30987213
Oncotarget. 2020 Mar 31;11(13):1186-1201
pubmed: 32284794
Anal Chim Acta. 2020 Aug 29;1127:140-148
pubmed: 32800117
Cancers (Basel). 2021 Jun 10;13(12):
pubmed: 34200529
Nat Commun. 2018 Jan 15;9(1):191
pubmed: 29335551
J Clin Invest. 2021 Jun 1;131(11):
pubmed: 33905375
Am J Pathol. 2015 Jun;185(6):1724-39
pubmed: 25892683
Surgery. 2012 Sep;152(3):449-54
pubmed: 22938903
Hepatol Int. 2017 Jul;11(4):317-370
pubmed: 28620797
Cancer Lett. 2018 Mar 28;417:21-34
pubmed: 29248714
Cancer Sci. 2020 Feb;111(2):406-417
pubmed: 31785057
J Gastroenterol. 2019 Nov;54(11):1007-1018
pubmed: 30941514
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
J Clin Invest. 2010 Sep;120(9):3326-39
pubmed: 20697159
Gastroenterology. 2018 Jun;154(8):2209-2221.e14
pubmed: 29454793
Gut. 2022 Jan;71(1):185-193
pubmed: 33431577
J Exp Clin Cancer Res. 2019 Apr 18;38(1):170
pubmed: 30999932
Int J Cancer. 2014 Feb 15;134(4):778-88
pubmed: 23929039
J Biol Chem. 2007 Aug 10;282(32):23337-47
pubmed: 17562716
Oncoimmunology. 2018 Oct 10;8(2):e1527650
pubmed: 30713782
Cancer Lett. 2013 Oct 1;339(1):70-81
pubmed: 23879969
Oncogene. 2017 Feb 23;36(8):1090-1101
pubmed: 27593937
Clin Gastroenterol Hepatol. 2008 Oct;6(10):1155-61
pubmed: 18639493
Anat Sci Int. 2017 Sep;92(4):387-455
pubmed: 28299597
Nat Commun. 2017 Oct 13;8(1):924
pubmed: 29030636
Elife. 2020 Oct 26;9:
pubmed: 33103995
Cancer Res. 2020 Sep 15;80(18):3892-3905
pubmed: 32591411
World J Gastroenterol. 2011 Mar 7;17(9):1192-8
pubmed: 21448425
Cell Death Discov. 2021 Oct 18;7(1):298
pubmed: 34663798
Clin Gastroenterol Hepatol. 2009 Nov;7(11 Suppl):S68-78
pubmed: 19896103
Cancers (Basel). 2021 Oct 13;13(20):
pubmed: 34680276
Physiol Rev. 2021 Jan 1;101(1):147-176
pubmed: 32466724
Hepatology. 2011 Sep 2;54(3):920-30
pubmed: 21674557
Hepatology. 2021 May;73(5):1717-1735
pubmed: 33682185
Cancer Lett. 2012 May 28;318(2):154-61
pubmed: 22182446
Cancer Lett. 2017 Sep 28;404:19-28
pubmed: 28716525
Br J Cancer. 2022 Feb;126(2):219-227
pubmed: 34616011
Carcinogenesis. 2014 Mar;35(3):597-605
pubmed: 24293410
Nat Rev Cancer. 2013 Oct;13(10):739-52
pubmed: 24060865
Ann Transl Med. 2020 Jul;8(14):856
pubmed: 32793700
Hepatology. 2018 Feb;67(2):762-773
pubmed: 28671339
Cancer Lett. 2016 Dec 1;383(1):18-27
pubmed: 27693460
Clin Exp Immunol. 2017 Apr;188(1):96-108
pubmed: 28019655
Nat Rev Endocrinol. 2016 Apr;12(4):203-21
pubmed: 26893264
Ann Surg Oncol. 2019 May;26(5):1552-1559
pubmed: 30805811
Mech Ageing Dev. 2011 Nov-Dec;132(11-12):533-42
pubmed: 22100852
Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14977-82
pubmed: 22927397
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
J Surg Res. 2014 Nov;192(1):117-23
pubmed: 24909871
BMC Cancer. 2015 Mar 27;15:188
pubmed: 25879842
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):186-196
pubmed: 26278673
Nat Rev Clin Oncol. 2022 Mar;19(3):151-172
pubmed: 34764464
J Pathol. 2016 May;239(1):109-21
pubmed: 26924336
Oncol Lett. 2018 Apr;15(4):4805-4812
pubmed: 29552120
Int J Cancer. 2012 Nov 15;131(10):2234-41
pubmed: 22337081
J Clin Invest. 2013 May;123(5):1911-8
pubmed: 23635789
Mol Cancer. 2010 Jan 24;9:13
pubmed: 20096135
Hepatology. 2022 Jan;75(1):28-42
pubmed: 34387870
J Cancer. 2018 Sep 7;9(18):3278-3286
pubmed: 30271487
Cancer Cell. 2021 Jun 14;39(6):883
pubmed: 34129825
Cells. 2020 May 26;9(6):
pubmed: 32466488
Cell Transplant. 2011;20(1):5-14
pubmed: 21396235
Clin Cancer Res. 2015 Jul 1;21(13):3081-91
pubmed: 25820415
Technol Cancer Res Treat. 2019 Jan-Dec;18:1533033819879905
pubmed: 31757187
Clin Cancer Res. 2012 Oct 1;18(19):5438-48
pubmed: 22891198
Hepatology. 2021 Sep;74(3):1578-1594
pubmed: 33817801
J Mol Med (Berl). 2019 Feb;97(2):243-255
pubmed: 30564864
Physiol Rev. 1996 Jan;76(1):69-125
pubmed: 8592733
Curr Opin Gastroenterol. 2011 May;27(3):276-84
pubmed: 21297470
Exp Hematol Oncol. 2018 Aug 03;7:17
pubmed: 30087805
Cancer Lett. 2021 Feb 28;499:243-254
pubmed: 33246092
Am J Cancer Res. 2018 Feb 01;8(2):302-316
pubmed: 29511600
Pathol Oncol Res. 2014 Jul;20(3):655-60
pubmed: 24482053
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Life Sci. 2022 Jan 1;288:120168
pubmed: 34826437
J Hepatol. 2012 Oct;57(4):813-20
pubmed: 22727731
Cancer Res. 2021 Nov 15;81(22):5692-5705
pubmed: 34551961
Mutat Res. 2005 Jan 6;569(1-2):29-63
pubmed: 15603751
EBioMedicine. 2018 May;31:1-2
pubmed: 29759482
Hepatology. 2013 Dec;58(6):2001-11
pubmed: 23787814
Cell Motil Cytoskeleton. 2005 Jan;60(1):24-34
pubmed: 15573414
J Cancer. 2021 Jan 1;12(5):1284-1294
pubmed: 33531974
Hepatology. 2012 Dec;56(6):2242-54
pubmed: 22711685
Cell Mol Life Sci. 2009 Jul;66(14):2219-30
pubmed: 19308325
Cancers (Basel). 2021 Feb 24;13(5):
pubmed: 33668153
PLoS One. 2013 May 07;8(5):e63243
pubmed: 23667593
J Cell Biochem. 2018 Nov;119(11):9419-9432
pubmed: 30015355
Hepatology. 2021 Dec;74(6):3194-3212
pubmed: 34297412
Trends Genet. 2011 Jun;27(6):224-32
pubmed: 21507500
J Biol Chem. 2018 Feb 2;293(5):1794-1809
pubmed: 29247004
Cancer Res. 2018 Sep 1;78(17):4902-4914
pubmed: 29967264
Nat Med. 2013 Dec;19(12):1617-24
pubmed: 24216753
J Hematol Oncol. 2020 Feb 5;13(1):11
pubmed: 32024555
Cell Death Dis. 2018 Mar 19;9(4):422
pubmed: 29556041
Front Immunol. 2021 Apr 30;12:643310
pubmed: 33995362
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Immunol Immunother. 2017 Aug;66(8):1025-1036
pubmed: 28401258
World J Gastroenterol. 2010 Feb 14;16(6):713-22
pubmed: 20135719
J Hepatol. 2019 Jul;71(1):104-114
pubmed: 30910538
Cancer Res Treat. 2021 Apr;53(2):457-470
pubmed: 33070556
J Exp Clin Cancer Res. 2018 Dec 27;37(1):324
pubmed: 30591064
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6
pubmed: 23420197
Hepatology. 2010 Apr;51(4):1438-44
pubmed: 20209607
Cancer Manag Res. 2019 Apr 10;11:2889-2901
pubmed: 31118769
Transl Oncol. 2021 Jan;14(1):100981
pubmed: 33395744
Cancers (Basel). 2021 Apr 28;13(9):
pubmed: 33925189
Cancer Cell Int. 2021 Jul 14;21(1):373
pubmed: 34261453
Front Cell Dev Biol. 2021 Nov 12;9:775462
pubmed: 34869376
Elife. 2018 Dec 24;7:
pubmed: 30582518
Hepatology. 2014 Feb;59(2):567-79
pubmed: 23960017
Clin Cancer Res. 2018 Sep 1;24(17):4282-4296
pubmed: 29716918
J Hepatol. 2019 Apr;70(4):700-709
pubmed: 30553841
Front Cell Dev Biol. 2021 Apr 06;9:631931
pubmed: 33889573
Cancer Res. 2019 Oct 15;79(20):5367-5381
pubmed: 31439548
Carcinogenesis. 2020 Apr 22;41(2):223-234
pubmed: 31140556
Cell Death Dis. 2021 Dec 6;12(12):1134
pubmed: 34873170